Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Tadao Ishida, Jun Ho Yi, Chandramouli Nagarajan et al. Nov 03, 2025 pp. 5815-5815 10.1182/blood-2025-5815

Abstract Introduction: Teclistamab (tec) is the first globally approved B-cell maturation antigen (BCMA) × CD3 bispecific antibody (BsAb) wi...

Incidence burden of AML across the US and Puerto Rico: A two-decade analysis of trends and disparities (1999-2021)

Ummul Asfeen, Muzamil Khan, Waseem Nabi et al. Nov 03, 2025 pp. 4435-4435 10.1182/blood-2025-4435

Abstract BACKGROUND: Acute myeloid leukemia (AML) is one of the most aggressive forms of hematologic malignancy of adults; its incidence inc...

Loss of cell cycle regulators RB1 and CDKN2A/2B induces CLL with distinct disease kinetics in murine models and shows distinct outcomes in CLL patients

Ivan Negara, Nevenka Ridova, Federico Jauk et al. Nov 03, 2025 pp. 3879-3879 10.1182/blood-2025-3879

Abstract Deletion of the RB1 gene, which encodes a tumor suppressor that inhibits cell cycle progression, is found in approximately 15% of c...

BTK regulates EZH2 stability in myeloid leukemia associated with down syndrome

Kader Cicek, Meredith Tavenner, Sonali Barwe et al. Nov 03, 2025 pp. 5071-5071 10.1182/blood-2025-5071

Abstract Children with Down syndrome (DS) have a significantly higher risk of developing acute myeloid leukemia (ML-DS), a distinct leukemia...

Long-term risk and racial disparities in second primary malignancies among diffuse large B-cell lymphoma survivors: A SEER-based analysis MP-SIR analysis (2000–2022)

Priyanka Nagdev, Sajed Salem, Alexandre Matboui et al. Nov 03, 2025 pp. 4556-4556 10.1182/blood-2025-4556

Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. With more...

Efficacy and prognostic determinants of BTK inhibitors in chronic lymphocytic leukemia (CLL): A real-world single-center cohort study from China

Xutao Guo, Yongqiang Wei, Xiaolei Wei et al. Nov 03, 2025 pp. 7421-7421 10.1182/blood-2025-7421

Abstract Background CLL is the most common adult leukemia in Western countries, with a rising incidence in China. Bruton's tyrosine kinase (...

Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT

Nikeshan Jeyakumar, Nancy Torres, Suneeta Godbole et al. Nov 03, 2025 pp. 2525-2525 10.1182/blood-2025-2525

Abstract Introduction Whether allogeneic hematopoietic cell transplantation (HCT) is curative for acute myeloid leukemia...

Epidemiology and outcomes of rosai-dorfman-destombes disease (RDD): A ten year single-center real world experience

Helen Gandler, Sachi Singhal, Christina Darwish et al. Nov 03, 2025 pp. 6540-6540 10.1182/blood-2025-6540

Abstract Introduction - Rosai-Dorfman disease (RDD) is a rare non-Langerhans cell histiocytosis that typically causes painless lymphadenopat...

Redefining what “on Hydroxyurea” means

Neha Bhasin, Kimberly Moffatt-Bazile, Julianne Nigro et al. Nov 03, 2025 pp. 6152-6152 10.1182/blood-2025-6152

Abstract Introduction Hydroxyurea (HU) has been shown to reduce hospitalizations, pain crises, mortality, and several long-term complication...

Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes

Yanli Zhao, Yue Lu, Deyan Liu et al. Nov 03, 2025 pp. 2493-2493 10.1182/blood-2025-2493

Abstract Introduction TP53-mutated hematologic malignancies carry a notoriously poor prognosis, particularly in cases with multi-hit TP53 al...

Single-cell multiomic profiling of gene mutation, chromatin accessibility, and gene expression in TET2-mutant clonal hematopoiesis

Masanori Motomura, Yotaro Ochi, Yasuhito Nannya et al. Nov 03, 2025 pp. 3164-3164 10.1182/blood-2025-3164

Abstract Introduction Age-related clonal hematopoiesis (CH) and clonal cytopenia of undetermined significance (CCUS) represent pre-leukemic c...

Impact of G6PD Α- mutation on hemoglobin function and RBC rheology in sickle cell disease

Temiloluwa Okusolubo, Akueba Bruce, Stephen Rogers et al. Nov 03, 2025 pp. 4702-4702 10.1182/blood-2025-4702

Abstract Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is the most common erythrocyte enzymopathy. Sickle cell disease (SCD) is an aut...

Proteomic analysis identifying biomarkers in the progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: A retrospective cohort study

Mingyu Jin, Sun Ting, Renchi Yang et al. Nov 03, 2025 pp. 1986-1986 10.1182/blood-2025-1986

Abstract Abstract: Objective:Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that can progress...

Beyond hemostasis: Factor VIII deficiency impacts  hematopoietic stem cells development in zebrafish

Watfa Ahmed, Dhanya Kizhakayil, Reem Yahia et al. Nov 03, 2025 pp. 4933-4933 10.1182/blood-2025-4933

Abstract Introduction Hemophilia A (HA) is a monogenic bleeding disorder caused by coagulation Factor (F) VIII deficiency. Recent studies su...

Clinical manifestations, risk factors and prognosis associated with central nervous system relapse after CAR-T therapy for R/R B-cell non-Hodgkin lymphoma: A multi-center analysis

Tianning Gu, Tingting Yang, Mengyu Zhao et al. Nov 03, 2025 pp. 6340-6340 10.1182/blood-2025-6340

Abstract Background Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment scheme of relapsed...

Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib

Eduardo Edelman Saul, Jessie Xu, Casey Bermack et al. Nov 03, 2025 pp. 5422-5422 10.1182/blood-2025-5422

Abstract Background Up to 75% of peripheral T-cell lymphoma (PTCL) patients (pts) treated with frontline CHOP-based therapy have relapsed/re...

Mitoxantrone liposome combined with EAC autologous transplant conditioning for the treatment of T/NK non-Hodgkin's lymphoma

Jiali Li, Dezhi Huang, Jun Rao et al. Nov 03, 2025 pp. 7156-7156 10.1182/blood-2025-7156

Abstract Objectives: New drug combination therapy can improve the survival rate of patients with T-cell lymphoma, but autologous hematopoiet...

Intrathecal versus intravenous methotrexate in diffuse large B-cell lymphoma: A real-world comparative outcomes study

Muhammad Bhinder, Maria Hashmi, Farhan Israr et al. Nov 03, 2025 pp. 5474-5474 10.1182/blood-2025-5474

Abstract Background: Methotrexate (MTX) is often administered either through intrathecal (IT) or intravenous (IV) routes along with R-CHOP c...

Racial disparities in clinical outcomes among patients with newly diagnosed and relapsed multiple myeloma in the United States: A 21-year comparative analysis

Tarfa Verinumbe, Chidiebube Ugwu, Elvis Obomanu et al. Nov 03, 2025 pp. 4600-4600 10.1182/blood-2025-4600

Abstract Background: Despite significant therapeutic advances, racial disparities persist across the continuum of care for patients with mul...

Characteristics and clinical course of younger Patients  with early lesions in a contemporary cohort of 1240 patients: Low risk features and low risk of complications

Eirini Solia, Foteini Theodorakakou, Panagiotis Malandrakis et al. Nov 03, 2025 pp. 2191-2191 10.1182/blood-2025-2191

Abstract Monoclonal Gammopathies of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and asymptomatic Waldenström's Macr...

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

Eitan Kugler, Jayastu Senapati, Sanam Loghavi et al. Nov 03, 2025 pp. 3206-3206 10.1182/blood-2025-3206

Abstract Background Aplastic anemia (AA) exhibits a bimodal age distribution with incidence peaks in young adults and patients aged >6...

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Ziyi Li, Kelly Chien, Yue Lyu et al. Nov 03, 2025 pp. 5644-5644 10.1182/blood-2025-5644

Abstract Background: Most patients with myelodysplastic syndromes (MDS) experience incomplete and short-lived responses to hypomethylating a...

Post transplantation cyclophosphamide (PTCy) combination with low-dose anti-thymocyte globulin (ATG) for gvhd prophylaxis in unmanipulated haploidentical peripheral blood stem cell transplantation without ATG in conditioning regimen

Hongyun Xing Nov 03, 2025 pp. 7710-7710 10.1182/blood-2025-7710

Abstract In haploidentical peripheral blood stem cell transplantation (haplo-PBSCT), the combination of anti-thymocyte globulin and post-tra...

Rising mortality attributed to agranulocytosis in myeloid leukemia among older adults in the United States : A time trend analysis

Ishani Shah, Pranay Vaghela, Vedant Shah et al. Nov 03, 2025 pp. 8157-8157 10.1182/blood-2025-8157

Abstract Introduction Agranulocytosis is a life-threatening complication in older adults with myeloid leukemia, yet its...

New evidence indicates that the NLRP3 inflammasome in hematopoietic stem and progenitor cells (HSPCs) maintains proper mitochondrial electron transport chain function and affects both cellular trafficking and metabolism through a gasdermin pore-mediated, alarmin-release-dependent mechanism

Magdalena Kucia, Michalina Kazek, Justyna Jarczak et al. Nov 03, 2025 pp. 2314-2314 10.1182/blood-2025-2314

Abstract Background . The Nlrp3 inflammasome is an intracellular pattern recognition receptor (PRR) and a key component of innate immunity,...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page